Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentaglobin early adjunctive treatment for febrile neutropenia in CRE or Pseudomonas-colonized acute leukemia or allo-HSCT patients
2018-001344-57Phase 2Active
- Sponsor
- GITMO
- Start
- Jun 2021
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Pentaglobin in febrile neutropenia (FN), carbapenem-resistant Enterobacterales bacteremia and bloodstream infection (BSI), sponsored by GITMO. Primary endpoint: 30-day mortality reduction in carriers developing pre-engraftment bloodstream infection due to CRE or Pseudomonas aeruginosa. Started Jun 2021; status: active.
02
Drugs
Pentaglobin
03
Conditions
febrile neutropenia (FN)carbapenem-resistant Enterobacterales bacteremiabloodstream infection (BSI)
Beyond the preview
Go deeper on 2018-001344-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001344-57.